1 / 1

ONTARGET

ONTARGET. Telmisartan (16.7%) noninferior; combination (16.3%) not superior to ramipril (16.5%) for primary endpoint (CV death, MI, stroke, heart failure) Greater incidence of hypotension in combination (4.8%) and telmisartan (2.7%) groups, compared with ramipril group (1.7%) (p < 0.001).

illiana-hunter
Télécharger la présentation

ONTARGET

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ONTARGET Telmisartan (16.7%) noninferior; combination (16.3%) not superior to ramipril (16.5%) for primary endpoint (CV death, MI, stroke, heart failure) Greater incidence of hypotension in combination (4.8%) and telmisartan (2.7%) groups, compared with ramipril group (1.7%) (p < 0.001) (p < 0.004*) (p = ns) Trial design:Patients at high risk for cardiovascular events, but without heart failure, were randomized to telmisartan, ramipril, or the combination. Patients were followed for a median of 56 months. Results 16.7 16.3 16.5 11.6 12.5 11.8 15 20 % 10 10 % 5 Conclusions • Either telmisartan or ramipril, but not both, can be used in hypertensive patients at high risk for cardiovascular events • Side effects greater with combination therapy 0 0 Primary endpoint Mortality Telmisartan (n = 8,542) Combination (n = 8,502) Ramipril (n = 8,576) * Telmisartan vs. ramipril for noninferiority The ONTARGET investigators. N Engl J Med 2008;358:1547-59

More Related